Funding Details
- Date Award
- May 18, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- Kernal Bio is in the late stages of securing a $48M in non-dilutive federal funding to advance KR-402 through Phase I clinical trials.
- Company Description
- Kernal Bio is an innovative mRNA 2.0 immunotherapy company developing a potentially transformative approach to cell therapy. The Company's proprietary technology combines selective mRNA delivery with targeted lipid nanoparticles (LNPs) to achieve precise in vivo cell engineering.
- Market
- Immunotherapy for blood cancers and autoimmune diseases
- Location
-
United States
- Coinvestors
- Hummingbird Ventures, Amgen Ventures, Civilization Ventures
Links